Boehringer Ingelheim has signed a deal with Enara Bio to explore the potential of what the UK biotech calls ‘dark antigens’ – antigens derived from the genomic ‘dark matter’ or the 98% of the genome that is not normally expressed, but which could yield many new targets for cancer immunotherapies.
Boehringer Explores ‘Dark Antigens’ With Enara In Potential $1bn Deal
Covers Novel Cancer Immunotherapy Targets And Therapies
Announcing its first big pharma deal, the Oxford-based biotech says there could be more to come – with mRNA pioneers also interested in shining a light on hidden drug targets.
More from Business
More from Scrip
• By
The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.
• By
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
• By
AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.